Propanc Biopharma Financials
| PPCB Stock | USD 8.89 6.13 222.10% |
Propanc |
Please note, the presentation of Propanc Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Propanc Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Propanc Biopharma's management manipulating its earnings.
Propanc Biopharma Stock Summary
Propanc Biopharma competes with Ocean Biomedical, Enveric Biosciences, Hepion Pharmaceuticals, Elevation Oncology, and Zura Bio. Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US74346N4043 |
| Business Address | 302, 6 Butler |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.propanc.com |
| Phone | 61 3 9882 0780 |
| Currency | USD - US Dollar |
Propanc Biopharma Key Financial Ratios
Propanc Biopharma's financial ratios allow both analysts and investors to convert raw data from Propanc Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Propanc Biopharma over time and compare it to other companies across industries.| Return On Asset | -13.07 | |||
| Target Price | 1.52 | |||
| Beta | 1.42 | |||
| Z Score | -85.8 |
Propanc Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Propanc Biopharma's current stock value. Our valuation model uses many indicators to compare Propanc Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Propanc Biopharma competition to find correlations between indicators driving Propanc Biopharma's intrinsic value. More Info.Propanc Biopharma is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Propanc Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Propanc Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Propanc Biopharma Systematic Risk
Propanc Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Propanc Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Propanc Biopharma correlated with the market. If Beta is less than 0 Propanc Biopharma generally moves in the opposite direction as compared to the market. If Propanc Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Propanc Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Propanc Biopharma is generally in the same direction as the market. If Beta > 1 Propanc Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Propanc Biopharma February 16, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Propanc Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Propanc Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Propanc Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Propanc Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Propanc Biopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 30.04 | |||
| Information Ratio | 0.1027 | |||
| Maximum Drawdown | 181.08 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 50.0 |
Complementary Tools for Propanc Pink Sheet analysis
When running Propanc Biopharma's price analysis, check to measure Propanc Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma is operating at the current time. Most of Propanc Biopharma's value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma's price. Additionally, you may evaluate how the addition of Propanc Biopharma to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |